Breakthrough for hepatocellular carcinoma

An oral multikinase inhibitor has come up trumps as a second-line treatment for hepatocellular carcinoma patients in a phase 3 trial which showed improved survival over placebo.

Gastroenterologists say results for regorafenib, published in The Lancet this week, offer a “glimpse of hope” towards curing HCC after ten years of failed trials.  

The Bayer-funded RESORCE trial randomised 374 patients to 160mg oral regorafenib